Rejuvenate Muscle Health™ Adds Prominent GLP-1 Support Call-Out to New Packaging Set to Debut Later This Month Across North America; ECRM "Best Drink 2025" Validation; Promino™ NSF Certified for Sport® Extends Amino Platform into Performance

Burlington, Ontario--(Newsfile Corp. - May 5, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a performance nutrition company focused on clinically validated amino acid formulations, announces it is aligning with a growing shift toward muscle health support as Health Canada approves additional generic semaglutide products, expanding access to GLP-1 therapies used for weight loss and metabolic health.

As GLP-1 medications become more widely used, attention is increasingly focused on maintaining lean muscle during weight loss - an important factor in supporting strength, mobility and overall health outcomes.

Rejuvenate Muscle Health™ is designed to meet this need with a clean, easy-to-use alternative to traditional protein powders. The product is sugar-free, dairy-free and low in calories, offering a refreshing option for individuals who want daily muscle support without heavy shakes or unnecessary additives.

The product's taste and consumer appeal were recognized at a leading industry buying event, where Rejuvenate Muscle Health™ was awarded "Best Drink - 2025" by category buyers across grocery, pharmacy and e-commerce channels.

Recent feedback from GLP-1 consumers using Rejuvenate Muscle Health™ has been strong, with users highlighting the product's ease of use and compatibility with reduced appetite and simplified eating patterns. In response, the Company has added a prominent GLP-1-focused PDP (product detail page) call-out on new packaging, which is scheduled to roll out across North America later this month. Rejuvenate Muscle Health™ was also recently featured in a streamed workshop focused on GLP-1 support solutions, including visibility across major e-commerce platforms such as Amazon.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11111/295906_rejuvenate_glp-1_pdp_photo_compressed.jpg

Beyond GLP-1 users, Rejuvenate Muscle Health™ is gaining traction among healthy aging consumers and active adults seeking to support strength, recovery and mobility as part of their everyday routines - particularly those looking for an alternative to high-calorie whey proteins often associated with excess sugars and fillers.

Promino™ NSF Certified for Sport® represents a higher-dose application of the Company's proprietary amino acid blend, developed for performance athletes. The formulation is designed to support muscle recovery and metabolic repair associated with high-intensity training and competition.

"Consumers are looking for simpler, cleaner ways to support their bodies every day," said Vito Sanzone, Chief Executive Officer. "Rejuvenate Muscle Health™ fits seamlessly into modern lifestyles, whether the goal is weight management, staying active or maintaining strength over time."

Promino continues to focus on expanding awareness of muscle health as a foundational component of overall wellness, with Rejuvenate Muscle Health™ positioned as a convenient daily solution across multiple consumer segments.

Closing of First Tranche of Private Placement

Promino is also pleased to announce that, further to its press releases dated March 13 and April 22, 2026, the Company has closed a first tranche (the "First Tranche") of its private placement, issuing an aggregate of 5,333,332 units ("Units") at a price of $0.03 per Unit for gross proceeds of $160,000. 3,333,333 of the Units are composed of one (1) common share of the Company (a "Share") and one (1) Share purchase warrant exercisable into one (1) additional Share at a price of $0.06 for three (3) years from the date of issuance. The remaining 1,999,999 Units are composed of one (1) Share and one half of one (1/2) Share purchase warrant, each whole warrant exercisable into one (1) additional Share at a price of $0.06 for one (1) year from the date of issuance.

In connection with the First Tranche, the Company paid finder's fees of $14,000 in cash, issued 333,333 finder's warrants, each exercisable into one (1) Share at a price of $0.06 for three (3) years from the date of issuance, and issued 133,333 finders warrants, each exercisable into one (1) Share at a price of $0.06 for one (1) year from the date of issuance.

The net proceeds from the First Tranche are expected to be used to (a) accelerate growth through investments in inventory and (b) fund general corporate purposes, excluding accrued salaries to officers or directors of the Company and payment for Investor Relations Activities (as such term is defined in the policies of the Canadian Securities Exchange).

All securities issued upon closing of the First Tranche are subject to a four month hold period in accordance with applicable securities laws.

The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Promino Nutritional Sciences Inc.

Promino Nutritional Sciences is a Canadian innovation company focused on science-based, clinically proven nutrition for muscle health and recovery. Its core product, Rejuvenate Muscle Health™, is a clinically researched proprietary amino acid formula designed to rebuild, restore, and rejuvenate muscle tissue.

The Company also produces Promino™ - NSF Certified for Sport®, trusted by elite athletes. Promino's ambassadors include Stanley Cup Champion Jack Eichel (Vegas Golden Knights) and MLB legend José Bautista.

Learn more at www.drinkpromino.com and www.rejuvenatemuscle.com.

Forward-Looking Statements and Financial Outlook

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are often, but not always, identified by terms such as "will", "may", "should", "anticipates", "expects", "intends", "plans", "believes", "estimates" and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements regarding: market trends and consumer demand for muscle health and GLP-1 support products; the anticipated rollout of new packaging across North America; the expected benefits and positioning of Rejuvenate Muscle Health™ and Promino™ NSF Certified for Sport®; the completion of the remainder of the Company's private placement; the anticipated use of proceeds of the First Tranche; and the receipt of all required regulatory approvals, including acceptance by the Canadian Securities Exchange. Forward-looking statements are based on a number of assumptions made by management that the Company believes to be reasonable in the circumstances, including assumptions regarding general economic and market conditions, continued consumer demand for the Company's products, the Company's ability to execute on its business plan, and the absence of material adverse changes affecting the Company or its industry. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or developments to differ materially from those expressed or implied by such statements, including, without limitation: the Company may not complete the remainder of its private placement on terms favorable to the Company or at all; the Canadian Securities Exchange may not approve the First Tranche or the remainder of the private placement; the proceeds of the First Tranche may not be used as stated in this news release; the Company may be unable to satisfy all of the conditions to closing of the private placement; product, regulatory and competitive risks affecting the consumer health and nutrition industry; and those additional risk factors described in the Company's continuous disclosure documents filed on SEDAR+ at www.sedarplus.ca, including the Company's most recent management's discussion and analysis. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned not to place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are made as of the date of this news release, and the Company does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

For further information about Promino:

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295906